Novavax, Inc. (NVAX) closed at $0.99 in the last trading session

TIAA CREF Investment Management downgraded its stake in Novavax, (NASDAQ:NVAX) by 18.2% during the Q1, Holdings Channel reports. Its minimum price target estimates has been figured out at $1.1 while the maximum price target forecast is established at $3.

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost.

United Nations chief: Racism, xenophobia, anti-Semitism or Islamophobia are poisoning our societies
Do you something awesome to share with the world? Download the Nigeria Today app from Play store. Racism, xenophobia, anti-Semitism or Islamophobia are...poisoning our societies.

Novavax, Inc. (NVAX) reported sales (ttm) of 21 Million, whereas, 5 number of analysts estimated the mean sale of 6.82 million. ValuEngine lowered the stock of Novavax from a "sell" recommendation to a "strong sell" recommendation in a analysis report on Friday morning, Jun 2nd. Cantor Fitzgerald fixed a $2.00 target price on the stock of Novavax and issued the shares a "hold" recommendation in a analysis note on Mon, May 8th. BidaskClub upgraded Novavax from a sell rating to a hold rating in a research note on Monday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock.

Novavax, Inc. (NASDAQ:NVAX) has noticeable measure of stock volatility, for this average true range is an exponential moving average (14 trading days) of the True Ranges. Novavax has a 12-month low of $0.73 and a 12-month high of $8.49. The company's 50 day moving average price is $1.13 and its 200 day moving average price is $1.14. The stock's market cap is $286.89 million. However a year ago for the same quarter the company has reported $-0.24 EPS. Novavax had a negative return on equity of 787.38% and a negative net margin of 1,006.00%. For the current year the company's revenue estimates are $26.87 Million compared to low analyst estimates of $24.4 Million and high estimates of $29.4 Million according to the prediction of 5 analysts. During the same quarter in the previous year, the business earned ($0.29) EPS. A month ago, they told us to expect earnings of US$-0.15 per share while three months ago their EPS consensus estimate was US$-0.15.

Le'Veon Bell to Return to Steelers Before Start of Regular Season
Bell is one of the game's best playmakers but plays in a positional market that appears tapped out at around $8 million per year.

COPYRIGHT VIOLATION NOTICE: This report was published by BBNS and is the sole property of of BBNS. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of USA & global copyright and trademark legislation. The legal version of this story can be viewed at

A number of institutional investors have recently bought and sold shares of NVAX. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company's stock valued at $139,000 after buying an additional 455 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Novavax during the first quarter worth $157,000. Geode Capital Management LLC now owns 2,400,960 shares of the biopharmaceutical company's stock worth $3,073,000 after buying an additional 371,295 shares during the period. Lastly, Teachers Advisors boosted its stake in stocks of Novavax by 4.2% in the Q4. Northern Trust Corp boosted its stake in shares of Novavax by 2.8% in the second quarter. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company's stock worth $213,000 after buying an additional 10,965 shares during the period. GSA Capital Partners LLP now owns 1,690,153 shares of the biopharmaceutical company's stock worth $1,944,000 after buying an additional 471,347 shares in the last quarter. The average volume of a stock suggests the liquidity of a particular company.

Alibaba Group Holding Limited
RBC Capital Markets maintained Alibaba Group Holding Ltd (NYSE: BABA ) on Wednesday, October 28 with "Outperform" rating. Capital Research Global Investors increased its position in Alibaba Group Holding Limited by 2.2% in the second quarter.

Related news